Balaxi Pharmaceuticals Ltd (BALAXI) — shareholding pattern, promoter holding, financials and share price
About Balaxi Pharmaceuticals Ltd (BALAXI)
Balaxi Pharmaceuticals Ltd operates in the Diversified industry. It trades on the NSE as BALAXI and on the BSE under scrip code 532597. Its ISIN is INE618N01022.
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
Balaxi Pharmaceuticals Limited is a branded, IPR-driven pharmaceutical company focused on OTC and branded generics in frontier markets across Latin America and Africa, operating an asset-light distribution network of 38 warehouses and owned fleet while sourcing finished products from WHO‑GMP contract manufacturers across India, China and Portugal and selling through its local subsidiaries.
In Q3 FY26 Balaxi completed commissioning, qualification and validation of its first in-house formulation facility at Jadcherla for general oral solid dosages, marking a deliberate move from 'asset-light' to 'asset-right' and enabling backward integration, faster regulatory approvals, improved quality control and expected margin enhancement as the plant begins commercial supply to LATAM and African markets.
Listed peers in Diversified: Maheshwari Logistics Ltd, Aspinwall & Company Ltd, Adani Enterprises Ltd Partly Paidup, KCK Industries Ltd, Krypton Industries Ltd, Panth Infinity Ltd.
Valuation & Returns
10 Jul 2026At ₹24.17 a share on 10 Jul 2026, Balaxi Pharmaceuticals Ltd (BALAXI) was valued at a price-to-earnings ratio of 93.97x against an industry P/E of 31.59x and a price-to-book of 0.58x on a book value of ₹41.97 per share as of Mar 2025. Solomo computes return on equity of 0.61% and return on capital employed of 3.23% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 93.97x
- Industry P/E
- 31.59x
- P/B
- 0.58x
- EPS (TTM)
- ₹0.26
- Book value / share
- ₹41.97
- ROE
- 0.61%
- ROCE
- 3.23%
- ROA
- 0.46%
- Debt / equity
- 0.23x
- Dividend yield
- 0%
- EBITDA margin
- 4.2%
- 52-week range
- ₹15.2 – ₹52.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Balaxi Pharmaceuticals Ltd (BALAXI) reported revenue of ₹270 crore, net profit of ₹1 crore and earnings per share of ₹0.26. That compares with revenue of ₹293 crore and net profit of ₹25 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹70.71 crore and net profit ₹0.61 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 279 | 336 | 241 | 293 | 270 |
| Net profit (₹ cr) | 48 | 46 | -2 | 25 | 1 |
| EPS (₹) | 9.53 | 9.03 | -0.44 | 4.54 | 0.26 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 121.50% | 5.97% | -15.56% | 21.25% |
| Profit growth | - | -11.13% | -37.38% | - |
| Stock price CAGR | 19% | -28% | -39% | -51% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 65.99% of Balaxi Pharmaceuticals Ltd (BALAXI) (unchanged from the previous quarter). Market capitalisation was ₹133 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2015.
Largest disclosed public shareholders in Jun 2026: RGSL INVESTMENT FUND - RGSL INVESTMENT LVF 1 2.54%, KUNAL MAHENDRA BHAKTA 1.86%, AMOL ANAND MANTRI 1.41%, P P ZIBI JOSE 1.29%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 65.99% | - | - | - | - |
| Mar 2026 | 65.99% | - | - | - | - |
| Dec 2025 | 65.99% | - | - | - | - |
| Sep 2025 | 65.99% | - | - | - | - |
| Jun 2025 | 65.99% | - | - | - | - |
| Mar 2025 | 65.99% | - | - | - | - |
| Dec 2024 | 65.99% | - | - | - | - |
| Sep 2024 | 65.99% | - | - | - | - |